查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2096493

口服固體製劑契約製造市場－2026-2032年全球預測

Oral Solid Dosage Contract Manufacturing Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，口服固體製劑的契約製造市場將成長至 199.6 億美元，複合年成長率為 9.15%。

主要市場統計數據
基準年 2025 108億美元
預計年份：2026年 117.7億美元
預測年份 2032 199.6億美元
複合年成長率 (%) 9.15%

口服固體製劑的契約製造是醫藥外包的關鍵支柱，為片劑、膠囊、粉末、顆粒劑、丸劑和緩釋製劑的研發和商業化生產提供支援。這項需求源於口服藥物在全球治療方案中持續的重要性、學名藥和專科藥物研發管線的不斷擴展，以及對符合現行藥品生產品質管理規範 (GMP) 要求的靈活生產能力的需求。製藥公司越來越依賴合約研發生產機構 (CDMO) 來進行製劑開發、分析測試、技術轉移、放大生產、驗證、包裝和生命週期管理。此外，隨著申辦者尋求高活性化合物、難溶性活性成分、兒童和老年人用藥製劑、固定劑量組合藥物以及緩釋製劑系統，該領域的技術要求也日益嚴格。目前，競爭優勢取決於監管信譽、品質系統的成熟度、供應鏈的韌性、數位化生產能力以及將產品從臨床批次高效過渡到商業規模口服固體製劑生產的能力。

正在重塑口服固體製劑生產產業的變革性變化。

隨著製藥公司調整內部產能、拓展供應商網路並加快產品研發進度，口服固體製劑的契約製造產業正經歷結構性變革。其中一個主要轉變是從簡單的交易外包轉向整合製劑科學、製程開發、法規文件、分析服務和商業化生產，並將其納入單一品質框架的夥伴關係。由於小分子化合物的研發管線中擴大包含需要職業暴露控制和特殊處理的高活性化合物，對具備隔離能力的設施的需求日益成長。同時，連續生產、先進的製粒技術、自動化檢測和即時製程監控也備受關注，因為當這些技術應用於經過驗證的品質系統時，可以提高批間一致性、減少偏差並支援更快的規模化生產。供應鏈策略也在發生變化，客戶正在評估地域冗餘、雙重採購、區域包裝和經認證的備用產能，以降低中斷風險。監管機構對資料完整性、污染控制、亞硝胺風險評估和可追溯性文件的要求，迫使製造商在口服固體製劑生產的每個階段加強品質管治。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過改進製劑設計、製程最佳化、預測性品管和營運規劃等方面的決策，對口服固體製劑的契約製造產生了累積的影響。在研發流程中，AI 驅動的建模有助於輔料適用性篩檢、溶離行為預測，並在生命週期早期識別關鍵物料特性和程式參數。在生產營運中，將機器學習與經過驗證的生產執行系統 (MES)、實驗室資訊系統 (LIS) 和流程分析技術 (PAT) 結合，可以支援偏差模式檢測、預測性維護、產量提升以及更有效的根本原因分析。 AI 還透過改進需求訊號分析、庫存計劃以及識別與關鍵原料和包裝組件相關的風險，增強了供應鏈管理。然而，其應用必須透過經過驗證的演算法、人工監督、網路安全措施、審計追蹤和證明透明度和可重複性的監管文件來管理。對契約製造製造商而言，人工智慧的實際價值不在於取代既定的品質體系，而在於補充科學判斷、加速調查，以及在合規的操作條件下更穩定地生產口服固體製劑。

來自全球製造地的關鍵區域洞察

亞太地區是口服固體製劑契約製造的重要中心，這得益於其大規模的製藥生產基地、不斷成長的熟練勞動力以及國內外市場對學名藥的強勁需求。該地區受益於成熟的活性成分（API）生態系統、不斷成長的GMP合規設施投資以及在片劑、膠囊、緩釋製劑和大規模生產方面積累的豐富經驗。歐洲的特點是成熟的品質標準、先進的製劑技術以及嚴格的序列化、藥物警戒文件、合格監管和生產可追溯性方面的監管要求。北美憑藉其嚴格的法規環境、活躍的臨床開發活動以及對複雜製劑支援、技術轉移和更貼近終端市場的商業化生產的需求，仍然保持著重要的地位。隨著拉丁美洲醫療保健覆蓋範圍的擴大以及製造商在品牌學名藥、固態製劑包裝和本地化供應鏈方面能力的提升，該地區的重要性日益凸顯。非洲正成為一個新興的機會區，這得益於人口成長、改善藥品可及性的努力以及建立更具韌性的本地和區域藥品供應鏈的舉措。儘管基礎設施、監管協調和技術能力在各國之間存在顯著差異，但非洲的發展潛力仍然巨大。在中東，藥品在地化、醫療安全和技術合作是優先事項，這為固態口服製劑的生產、重新包裝和區域分銷創造了機會。

關鍵的群體洞察，用於策略性地調整製造結構

儘管北約成員國並非藥品貿易集團，但從供應安全角度來看，它們的重要性日益凸顯，因為各國政府都在評估藥品的可及性、戰略儲備和生產連續性，以滿足關鍵的醫療保健需求。七國集團（G7）透過其嚴格的監管要求、創新主導的藥物研發、嚴謹的檢查文化以及對具有韌性和透明度的藥品供應鏈的需求，持續影響著高標準的藥品外包實踐。金磚國家（BRICS）擁有大規模的患者群體、對學名藥的需求、完善的國內產業政策以及在製劑和工藝放大方面日益成長的技術專長，從而為藥品生產能力和消費提供了廣闊的基礎。歐盟（EU）為口服固體製劑提供了最完善的法規環境之一，高度重視藥品生產品質管理規範（GMP）合規性、合格的監管、序列化、資料完整性和統一的市場准入程序。在東南亞國協，隨著成員國發展醫藥產業園區、加強監管合作以及支持區域基本學名藥的生產，口服固體製劑的契約製造的重要性日益凸顯。海灣合作理事會國家正透過對醫療保健產業的投資、採購改革和產業多元化計畫來推動藥品在地化，從而對在口服固體製劑的生產、包裝和品質轉移方面擁有檢驗能力的合作夥伴產生需求。

影響外包決策的主要國家趨勢

中國正憑藉大規模生產、先進的原料藥整合、完善的品質體係以及與國際標準更加緊密的監管接軌，擴大其成品固態製劑的生產能力。美國是固態製劑契約製造的主要需求中心，這得益於其廣泛的藥物研發活動、嚴格的法律規範以及對國內或近岸供應鏈韌性的持續關注。日本對高品質、準確的文件和以患者為中心的給藥標準有著極高的要求，因此對專業化生產、製劑最佳化和全生命週期支援的需求日益成長。印度是全球領先的非專利口服固體製劑供應商，擁有豐富的製劑專業知識、監管申報經驗和大規模的生產基礎設施。德國以其卓越的工程技術、完善的藥品品質系統和先進的生產能力而聞名，而英國則在製劑開發、臨床試驗藥物供應、監管科學和專業生產技術方面繼續發揮重要作用。澳洲為藥品生產、臨床試驗藥物供應和區域分銷提供了完善的監管環境，而法國則支持所有固態製劑的高標準藥品生產和監管合規。韓國擁有先進的工業基礎設施、完善的品管體系，以及快速成長的藥品研發和生產服務能力。義大利和西班牙仍然是重要的歐洲生產中心，在契約製造、包裝和出口型醫藥業務方面擁有豐富的經驗。加拿大提供穩定的監管和臨床研究環境，並為北美市場特製固態製劑的研發、包裝和供應支援提供了機會。俄羅斯重視國內藥品生產能力和供應自主性，尤其是在基本藥物方面。巴西是拉丁美洲的主要藥品市場，對學名藥、品牌學名藥和本地生產夥伴關係的需求旺盛。同時，墨西哥擁有許多優勢，例如地理位置接近性美國、擁有成熟的藥品生產體系，以及在近岸外包策略中日益重要的地位。

為行業領導者提供的實用建議

產業領導者應優先考慮整體品質主導的差異化策略，透過投資強大的污染控制、資料完整性系統、偏差管理和審計準備，提升口服固體製劑業務的競爭力。製造商需要拓展其在複雜固態製劑形式（包括緩釋片、多顆粒製劑、高活性產品、固定劑量組合藥物和難溶性化合物）方面的生產能力，因為這些領域比標準速釋製劑的生產需要更深厚的技術專長。申辦者和製造商應儘早建立整合的技術轉移模式，明確定義關鍵品質屬性、程式參數、分析方法和驗證責任。應透過認證的二級供應商、區域包裝方案、雙廠址​​策略和透明的原料風險評估來增強供應韌性。數位轉型應專注於已驗證的系統，以提高批次記錄的準確性、流程視覺性、預測性維護和法規可追溯性。此外，由於技術人員在可靠的契約製造中仍發揮核心作用，經營團隊還應投資於員工的GMP合規性、隔離程序、分析科學和數位化工具的培訓。

調查方法

本執行摘要採用系統的二手研究方法編寫，重點關注經檢驗且有數據支持的行業信息，這些信息來自監管指南、藥品生產標準、公共衛生機構、貿易文件、科學文獻以及公開的行業信息。本分析著重於定性的市場動態，而非數值化的市場估算、市場規模計算、佔有率評估或預測。研究途徑資料探討了口服固體製劑契約製造生產與製劑開發、GMP合規性、品質系統、供應鏈韌性、區域生產能力、監管預期以及新興技術應用等領域的相關性。透過對藥品生產環境、監管成熟度、醫療保健准入優先事項、外包促進因素和供應穩定措施的比較檢驗，整合了區域、群體和國家層面的具體見解。研究結果透過跨多個資訊來源的一致性檢定進行檢驗，以確保結論反映已記錄的行業趨勢和實際情況。

結論

口服固體製劑的契約製造正從單純的產能外包服務轉向以品質主導的策略夥伴關係模式，以支持複雜的配方、穩健的供應鏈和快速的產品生命週期管理。最大的機會在於技術專長、卓越的法規遵從、數位化製造以及從研發到商業化全程提供一致服務的能力。人工智慧、先進的製程監控和改進的數據系統預計將在經過檢驗規框架內提升營運可靠性。從區域趨勢來看，現有製造地仍然至關重要，而新興中心則因本地化趨勢、對醫療保健行業的投資以及對供應穩定性的關注而日益重要。對於製藥公司和契約製造，長期成功取決於在整個全球口服固體製劑價值鏈中整合科學知識、秉持品質至上的文化、保持地理柔軟性以及實現透明運營。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：口服固體製劑的契約製造市場：依劑型分類

  • 藥片
    • 咀嚼片
    • 舌下片
  • 膠囊
    • 硬明膠膠囊
    • 軟膠囊
  • 粉末
    • 散裝粉末
    • 小袋
  • 顆粒
  • 顆粒

第8章：口服固體製劑的契約製造市場：依治療領域分類

  • 抗感染藥物
    • 抗生素
    • 抗病毒藥物
  • 心血管系統
    • 高血脂症
    • 高血壓
  • 中樞神經系統
    • 憂鬱症
    • 癲癇
  • 消化器官系統
    • 抑酸劑
    • 運動興奮劑
  • 腫瘤學
    • 血液疾病
    • 固態腫瘤

第9章：口服固體製劑的契約製造市場：依階段分類

  • 臨床試驗
  • 商業的

第10章：口服固體製劑的契約製造市場：依服務類型分類

  • 配方開發
    • 預配方評估
    • 原型開發
  • 製程開發
    • 製粒製程開發
    • 壓縮製程開發
  • 分析與發展
    • 穩定性測試
    • 溶離度試驗
  • 技術轉移服務
  • 商業製造服務

第11章：口服固體製劑的契約製造市場：依應用領域分類

  • 新藥研發
  • 學名藥的生產
  • 配方重新設計服務
  • 生命週期管理

第12章：口服固體製劑的契約製造市場：依最終用戶分類

  • 生技公司
  • 學術研究機構
  • 虛擬製藥公司
  • 製藥公司

第13章：口服固體製劑契約製造市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章：口服固體製劑的契約製造市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章：口服固體製劑契約製造市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Acino International AG
  • Aenova Group GmbH
  • Alcami Corporation
  • Alkem Laboratories Ltd.
  • Almac Group Ltd.
  • Aurobindo Pharma Ltd.
  • Beximco Pharmaceuticals Ltd.
  • Boehringer Ingelheim International GmbH
  • Bora Pharmaceuticals Co., Ltd.
  • Cambrex Corporation
  • Cipla Ltd.
  • Corden Pharma International GmbH
  • Delpharm SAS
  • Divi's Laboratories Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Famar SA
  • Fareva SA
  • Granules India Ltd.
  • Hermes Pharma GmbH
  • Hetero Drugs Ltd.
  • Jubilant Pharmova Ltd.
  • Lonza Group AG
  • NextPharma Technologies Holding Ltd.
  • PCI Pharma Services LLC
  • Pfizer Inc.
  • Piramal Pharma Ltd.
  • Recipharm AB
  • Thermo Fisher Scientific Inc.
Product Code: MRR-0D217D5AE60A

The Oral Solid Dosage Contract Manufacturing Market is projected to grow by USD 19.96 billion at a CAGR of 9.15% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.80 billion
Estimated Year [2026] USD 11.77 billion
Forecast Year [2032] USD 19.96 billion
CAGR (%) 9.15%

Oral solid dosage contract manufacturing is a critical pillar of pharmaceutical outsourcing, supporting the development and commercial production of tablets, capsules, powders, granules, pellets, and modified-release formulations. Demand is being shaped by the continued importance of oral medicines in global therapy regimens, the expansion of generic and specialty drug pipelines, and the need for flexible manufacturing capacity that complies with current good manufacturing practice requirements. Pharmaceutical sponsors increasingly rely on contract development and manufacturing organizations for formulation development, analytical testing, technology transfer, scale-up, validation, packaging, and lifecycle management. The sector is also becoming more technically demanding as sponsors pursue high-potency compounds, poorly soluble active pharmaceutical ingredients, pediatric and geriatric-friendly formats, fixed-dose combinations, and controlled-release delivery systems. Competitive advantage now depends on regulatory reliability, quality systems maturity, supply chain resilience, digital manufacturing capabilities, and the ability to move products efficiently from clinical batches to commercial-scale oral solid dosage production.

Transformative Shifts Reshaping Oral Solid Dosage Manufacturing

The oral solid dosage contract manufacturing landscape is undergoing structural change as pharmaceutical companies rebalance internal capacity, diversify supplier networks, and accelerate product development timelines. A major shift is the move from transactional outsourcing toward integrated partnerships that combine formulation science, process development, regulatory documentation, analytical services, and commercial manufacturing under one quality framework. Demand for containment-enabled facilities is rising as more small-molecule pipelines include potent compounds requiring occupational exposure control and specialized handling. At the same time, continuous manufacturing, advanced granulation technologies, automated inspection, and real-time process monitoring are gaining attention because they can improve batch consistency, reduce deviations, and support faster scale-up when implemented within validated quality systems. Supply chain strategy is also changing, with sponsors evaluating geographic redundancy, dual sourcing, regional packaging, and qualified backup capacity to reduce disruption risk. Regulatory expectations around data integrity, contamination control, nitrosamine risk assessment, and traceable documentation are pushing manufacturers to strengthen quality governance across every stage of oral solid dosage production.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating a cumulative impact across oral solid dosage contract manufacturing by improving decision-making in formulation design, process optimization, predictive quality, and operational planning. In development workflows, AI-enabled modeling can help screen excipient compatibility, predict dissolution behavior, and identify critical material attributes and process parameters earlier in the lifecycle. In manufacturing operations, machine learning can support deviation pattern detection, predictive maintenance, yield improvement, and more effective root-cause analysis when integrated with validated manufacturing execution systems, laboratory information systems, and process analytical technology. AI also strengthens supply chain control by improving demand signal analysis, inventory planning, and risk identification for critical raw materials and packaging components. However, adoption must be governed by validated algorithms, human oversight, cybersecurity controls, audit trails, and regulatory documentation that demonstrates transparency and reproducibility. For contract manufacturers, the practical value of AI lies not in replacing established quality systems but in augmenting scientific judgment, accelerating investigations, and enabling more consistent oral solid dosage production under compliant operating conditions.

Key Regional Insights Across Global Manufacturing Hubs

Asia-Pacific is a major hub for oral solid dosage contract manufacturing due to its large pharmaceutical production base, expanding skilled workforce, and strong demand for generic medicines across domestic and export markets. The region benefits from established active pharmaceutical ingredient ecosystems, increasing investment in GMP-compliant facilities, and growing expertise in tablets, capsules, modified-release formulations, and high-volume production. Europe is defined by mature quality standards, advanced formulation know-how, and strong regulatory expectations for serialization, pharmacovigilance documentation, qualified person oversight, and manufacturing traceability. North America remains highly influential because of its stringent regulatory environment, deep clinical development activity, and demand for complex formulation support, technology transfer, and commercial manufacturing close to end markets. Latin America is gaining relevance as regional healthcare access expands and manufacturers strengthen capabilities for branded generics, solid dose packaging, and localized supply. Africa is an emerging opportunity area where demand is supported by population growth, access-to-medicine initiatives, and efforts to build more resilient local and regional pharmaceutical supply chains, although infrastructure, regulatory harmonization, and technical capacity vary significantly across countries. The Middle East is prioritizing pharmaceutical localization, healthcare security, and technology partnerships, creating opportunities for oral solid dosage production, secondary packaging, and regional distribution.

Key Group Insights for Strategic Manufacturing Alignment

NATO member countries, while not a pharmaceutical trade bloc, are increasingly relevant from a supply security perspective as governments assess medicine availability, strategic reserves, and manufacturing continuity for critical healthcare needs. The G7 continues to influence high-standard outsourcing practices through advanced regulatory expectations, innovation-driven drug development, strong inspection cultures, and demand for resilient, transparent pharmaceutical supply chains. BRICS countries represent a broad base of pharmaceutical manufacturing capability and medicine consumption, combining large patient populations, generic medicine demand, domestic industrial policy, and growing technical expertise in formulation and process scale-up. The European Union provides one of the most sophisticated regulatory environments for oral solid dosage products, with strong emphasis on GMP compliance, qualified person oversight, serialization, data integrity, and harmonized market authorization procedures. ASEAN is becoming increasingly important for oral solid dosage contract manufacturing as member economies develop pharmaceutical industrial parks, strengthen regulatory cooperation, and support regional production of essential medicines and generics. The GCC is advancing pharmaceutical localization through healthcare investment, procurement reforms, and industrial diversification programs, creating demand for partners with validated oral solid dosage manufacturing, packaging, and quality transfer capabilities.

Key Country Insights Shaping Outsourcing Decisions

China has deep manufacturing scale, API integration, and expanding capabilities in finished oral solid dosage production under upgraded quality systems and stricter regulatory alignment with international standards. The United States is a leading demand center for oral solid dosage contract manufacturing, supported by extensive drug development activity, rigorous regulatory oversight, and ongoing interest in domestic or nearshore supply resilience. Japan requires high quality, documentation precision, and patient-centric dosage standards, creating demand for specialized manufacturing, formulation refinement, and lifecycle support. India is a central global supplier of generic oral solid dosage medicines, supported by extensive formulation expertise, regulatory filing experience, and large-scale manufacturing infrastructure. Germany is recognized for strong engineering, pharmaceutical quality systems, and advanced production capabilities, while the United Kingdom remains important for formulation development, clinical trial supply, regulatory science, and specialized manufacturing expertise. Australia provides a well-regulated environment for pharmaceutical production, clinical supply, and regional distribution, while France supports high-standard pharmaceutical manufacturing and regulatory compliance across solid dose formats. South Korea combines advanced industrial infrastructure, strong quality systems, and growing capability in pharmaceutical development and manufacturing services. Italy and Spain remain important European production bases with experience in contract manufacturing, packaging, and export-oriented pharmaceutical operations. Canada offers a stable regulatory and clinical research environment, with opportunities in specialized solid dose development, packaging, and North American supply support. Russia has emphasized domestic pharmaceutical production capacity and supply autonomy, particularly for essential medicines. Brazil is a key Latin American pharmaceutical market with demand for generics, branded generics, and local manufacturing partnerships, while Mexico benefits from proximity to the United States, established pharmaceutical manufacturing activity, and growing relevance in nearshoring strategies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize quality-led differentiation by investing in robust contamination control, data integrity systems, deviation management, and audit readiness across oral solid dosage operations. Manufacturers should expand capabilities in complex solid dose formats, including modified-release tablets, multiparticulates, high-potency products, fixed-dose combinations, and poorly soluble compounds, as these areas require deeper technical expertise than standard immediate-release production. Sponsors and manufacturers should establish integrated technology transfer models with clear critical quality attributes, process parameters, analytical methods, and validation responsibilities defined early. Supply resilience should be strengthened through qualified secondary suppliers, regional packaging options, dual-site strategies, and transparent material risk assessments. Digital transformation should focus on validated systems that improve batch record accuracy, process visibility, predictive maintenance, and regulatory traceability. Leaders should also invest in workforce training for GMP compliance, containment operations, analytical science, and digital tools, since technical talent remains central to reliable contract manufacturing performance.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified, data-backed industry intelligence from regulatory guidance, pharmaceutical manufacturing standards, public health agencies, trade documentation, scientific literature, and publicly available industry disclosures. The analysis emphasizes qualitative market dynamics rather than numerical market estimation, sizing, share assessment, or forecasting. Research inputs are reviewed for relevance to oral solid dosage contract manufacturing, including formulation development, GMP compliance, quality systems, supply chain resilience, regional manufacturing capability, regulatory expectations, and emerging technology adoption. Regional, group, and country insights are synthesized through comparative assessment of pharmaceutical production environments, regulatory maturity, healthcare access priorities, outsourcing drivers, and supply security initiatives. Findings are validated through cross-source consistency checks to ensure that conclusions reflect documented industry trends and operational realities.

Conclusion

Oral solid dosage contract manufacturing is evolving from a capacity-based outsourcing service into a strategic, quality-driven partnership model that supports complex formulations, resilient supply chains, and accelerated product lifecycle execution. The strongest opportunities are linked to technical specialization, regulatory excellence, digital manufacturing, and the ability to provide integrated development-to-commercial services. Artificial intelligence, advanced process monitoring, and improved data systems are expected to enhance operational reliability when implemented within validated compliance frameworks. Regional dynamics show that established manufacturing centers remain essential, while emerging hubs are gaining importance through localization, healthcare investment, and supply security priorities. For pharmaceutical sponsors and contract manufacturers, long-term success will depend on aligning scientific capability, quality culture, geographic flexibility, and transparent execution across the global oral solid dosage value chain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Oral Solid Dosage Contract Manufacturing Market, by Form Type

  • 7.1. Introduction
  • 7.2. Tablets
    • 7.2.1. Chewable Tablets
    • 7.2.2. Sublingual Tablets
  • 7.3. Capsules
    • 7.3.1. Hard Gelatin Capsules
    • 7.3.2. Soft Gelatin Capsules
  • 7.4. Powders
    • 7.4.1. Bulk Powders
    • 7.4.2. Sachets
  • 7.5. Granules
  • 7.6. Pellets

8. Oral Solid Dosage Contract Manufacturing Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Anti Infectives
    • 8.2.1. Antibiotics
    • 8.2.2. Antivirals
  • 8.3. Cardiovascular
    • 8.3.1. Hyperlipidemia
    • 8.3.2. Hypertension
  • 8.4. Central Nervous System
    • 8.4.1. Depression
    • 8.4.2. Epilepsy
  • 8.5. Gastrointestinal
    • 8.5.1. Acid Reducers
    • 8.5.2. Prokinetics
  • 8.6. Oncology
    • 8.6.1. Hematological
    • 8.6.2. Solid Tumor

9. Oral Solid Dosage Contract Manufacturing Market, by Stage

  • 9.1. Introduction
  • 9.2. Clinical Trial
  • 9.3. Commercial

10. Oral Solid Dosage Contract Manufacturing Market, by Service Type

  • 10.1. Introduction
  • 10.2. Formulation Development
    • 10.2.1. Preformulation Studies
    • 10.2.2. Prototype Development
  • 10.3. Process Development
    • 10.3.1. Granulation Process Development
    • 10.3.2. Compression Process Development
  • 10.4. Analytical Development
    • 10.4.1. Stability Testing
    • 10.4.2. Dissolution Testing
  • 10.5. Tech Transfer Services
  • 10.6. Commercial Manufacturing Services

11. Oral Solid Dosage Contract Manufacturing Market, by Application

  • 11.1. Introduction
  • 11.2. New Drug Development
  • 11.3. Generic Drug Manufacturing
  • 11.4. Reformulation Services
  • 11.5. Lifecycle Management

12. Oral Solid Dosage Contract Manufacturing Market, by End User

  • 12.1. Introduction
  • 12.2. Biotechnology Companies
  • 12.3. Academic & Research Institutes
  • 12.4. Virtual Pharma Companies
  • 12.5. Pharmaceutical Companies

13. Oral Solid Dosage Contract Manufacturing Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Oral Solid Dosage Contract Manufacturing Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Oral Solid Dosage Contract Manufacturing Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Acino International AG
  • 17.2. Aenova Group GmbH
  • 17.3. Alcami Corporation
  • 17.4. Alkem Laboratories Ltd.
  • 17.5. Almac Group Ltd.
  • 17.6. Aurobindo Pharma Ltd.
  • 17.7. Beximco Pharmaceuticals Ltd.
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Bora Pharmaceuticals Co., Ltd.
  • 17.10. Cambrex Corporation
  • 17.11. Cipla Ltd.
  • 17.12. Corden Pharma International GmbH
  • 17.13. Delpharm SAS
  • 17.14. Divi's Laboratories Ltd.
  • 17.15. Dr. Reddy's Laboratories Ltd.
  • 17.16. Famar S.A.
  • 17.17. Fareva SA
  • 17.18. Granules India Ltd.
  • 17.19. Hermes Pharma GmbH
  • 17.20. Hetero Drugs Ltd.
  • 17.21. Jubilant Pharmova Ltd.
  • 17.22. Lonza Group AG
  • 17.23. NextPharma Technologies Holding Ltd.
  • 17.24. PCI Pharma Services LLC
  • 17.25. Pfizer Inc.
  • 17.26. Piramal Pharma Ltd.
  • 17.27. Recipharm AB
  • 17.28. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHEWABLE TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHEWABLE TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHEWABLE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SUBLINGUAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SUBLINGUAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SUBLINGUAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HARD GELATIN CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HARD GELATIN CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HARD GELATIN CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SOFT GELATIN CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SOFT GELATIN CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SOFT GELATIN CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POWDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POWDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POWDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BULK POWDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BULK POWDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BULK POWDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SACHETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SACHETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SACHETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GRANULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GRANULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GRANULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PELLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PELLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PELLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI INFECTIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI INFECTIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HYPERLIPIDEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HYPERLIPIDEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HYPERLIPIDEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HYPERTENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HYPERTENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DEPRESSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DEPRESSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DEPRESSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL EPILEPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL EPILEPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL EPILEPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROINTESTINAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GASTROINTESTINAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROINTESTINAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ACID REDUCERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACID REDUCERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ACID REDUCERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROKINETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PROKINETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROKINETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEMATOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HEMATOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEMATOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SOLID TUMOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SOLID TUMOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SOLID TUMOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CLINICAL TRIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CLINICAL TRIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CLINICAL TRIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMMERCIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COMMERCIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMMERCIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PREFORMULATION STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PREFORMULATION STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PREFORMULATION STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PROTOTYPE DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PROTOTYPE DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROTOTYPE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GRANULATION PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GRANULATION PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GRANULATION PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL COMPRESSION PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL COMPRESSION PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL COMPRESSION PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANALYTICAL DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANALYTICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANALYTICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL STABILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL STABILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL STABILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DISSOLUTION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DISSOLUTION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DISSOLUTION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL TECH TRANSFER SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL TECH TRANSFER SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL TECH TRANSFER SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL COMMERCIAL MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL COMMERCIAL MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL COMMERCIAL MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEW DRUG DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEW DRUG DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEW DRUG DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GENERIC DRUG MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENERIC DRUG MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GENERIC DRUG MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL REFORMULATION SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL REFORMULATION SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL REFORMULATION SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL LIFECYCLE MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL LIFECYCLE MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL LIFECYCLE MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL VIRTUAL PHARMA COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL VIRTUAL PHARMA COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL VIRTUAL PHARMA COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 263. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 264. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2018-2032 (USD MILLION)
  • TABLE 265. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 266. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 267. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 268. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 269. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 270. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 272. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 274. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 275. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 276. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 281. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 282. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 284. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 285. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 286. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 287. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 288. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 290. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 292. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 293. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 294. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 295. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 318. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2018-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 320. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 322. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 324. EUROPEAN UNION ORAL SOLID